Quarterly report pursuant to Section 13 or 15(d)

Operating Segments (Tables)

Operating Segments (Tables)

9 Months Ended

Sep. 30, 2024

Schedule of Segment Reporting Information

Segment Reporting for the Quarter Ended September 30, 2024

										(1)
	Treatment			Services			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	9,064		$	7,748		$	16,812		$	—		$	16,812
Intercompany revenues		13			23			36			—			—
Gross profit		410			924			1,334			—			1,334
Research and development		205			34			239			64			303
Interest income		6			—			6			286			292
Interest expense		(37	)		(3	)		(40	)		(81	)		(121	⁾
Interest expense-financing fees		—			—			—			(18	)		(18	⁾
Depreciation and amortization		370			44			414			19			433
Segment loss		(4,902	)		(2,294	)		(7,196	)		(1,610	)		(8,806	)⁽⁴⁾
Expenditures for segment assets		1,203			180			1,383			—			1,383	⁽²⁾

Segment Reporting for the Quarter Ended September 30, 2023

										⁽¹⁾
	Treatment			Services			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	10,795		$	11,082		$	21,877		$	—		$	21,877
Intercompany revenues		4			88			92			—			—
Gross profit		1,494			3,055			4,549			—			4,549
Research and development		102			1			103			17			120
Interest income		—			—			—			146			146
Interest expense		(23	)		(1	)		(24	)		(65	)		(89	⁾
Interest expense-financing fees		—			—			—			(36	)		(36	⁾
Depreciation and amortization		584			88			672			14			686
Segment income (loss)		1,014			1,120			2,134			(1,888	)		246
Expenditures for segment assets		333			7			340			—			340	⁽³⁾

Segment Reporting for the Nine Months Ended September 30, 2024

										⁽¹⁾
	Treatment			Services			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	26,116		$	18,299		$	44,415		$	—		$	44,415
Intercompany revenues		67			52			119			—			—
Gross (loss) profit		(839	)		247			(592	)		—			(592	⁾
Research and development		609			87			696			176			872
Interest income		7			—			7			672			679
Interest expense		(107	)		(4	)		(111	)		(235	)		(346	⁾
Interest expense-financing fees		—			—			—			(47	)		(47	⁾
Depreciation and amortization		1,104			133			1,237			58			1,295
Segment loss		(7,416	)		(3,713	)		(11,129	)		(4,920	)		(16,049	)⁽⁴⁾
Expenditures for segment assets		1,820			404			2,224			—			2,224	⁽²⁾

Segment Reporting for the Nine Months Ended September 30, 2023

										⁽¹⁾
	Treatment			Services			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	33,223		$	33,793		$	67,016		$	—		$	67,016
Intercompany revenues		234			124			358			—			—
Gross profit		5,237			6,837			12,074			—			12,074
Research and development		260			11			271			69			340
Interest income		—			—			—			445			445
Interest expense		(68	)		(2	)		(70	)		(119	)		(189	⁾
Interest expense-financing fees		—			—			—			(80	)		(80	⁾
Depreciation and amortization		1,745			337			2,082			42			2,124
Segment income (loss)		2,619			2,933			5,552			(5,104	)		448
Expenditures for segment assets		1,376			10			1,386			—			1,386	⁽³⁾

⁽¹⁾

Amounts reflect the activity for corporate headquarters not included in the segment information.

⁽²⁾

Net of financed amount of $361,000 and $406,000 for the three and nine months ended September 30, 2024, respectively.

⁽³⁾

Net of financed amount of $152,000 and $309,000 for the three and nine months ended September 30, 2023, respectively.

⁽⁴⁾

Includes tax expense recorded in the amount of approximately $6,417,000 in the third quarter of 2024 in connection with a full valuation allowance against the Company’s U.S. deferred tax assets (see “Note 13 – Income Taxes” below for a discussion of this tax expense).